30670541, 30901819) and funds from the Zhejiang Provincial Extrem

30670541, 30901819) and funds from the Zhejiang Provincial Extremely Key Subject Building Project “”Pharmacology and Biochemical Pharmaceutics 2008″”. References 1. Afqir S, Ismaili N, Errihani H: Concurrent Emricasan cell line chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status. J Cancer Res Ther 2009, 5:3–7.PubMedCrossRef 2. Shanmugaratnam KSL: Histological Typing of Tumours of the Upper Respiratory Tract and Ear. In WHO. World Health Organization. International Histological

Classification of Tumours. 2nd edition. Berlin, Springer; 1996. 3. Yu WM, Hussain SS: Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia: review. J Laryngol Otol 2009, 123:1067–1074.PubMedCrossRef 4. McDermott AL, Dutt SN, Watkinson JC: The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001, 26:82–92.PubMedCrossRef 5. Yu MC, Yuan JM: Epidemiology of nasopharyngeal carcinoma. eFT508 mw Semin Cancer Biol 2002, 12:421–429.PubMedCrossRef 6. Zhang PJ, Weber R, Liang HH, Pasha TL, LiVolsi VA: Growth factors and receptors in juvenile nasopharyngeal angiofibroma and nasal polyps: an immunohistochemical

study. Arch Pathol Lab Med 2003, 127:1480–1484.PubMed SC79 ic50 7. Saylam G, Yucel OT, Sungur A, Onerci M: Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol 2006, 70:227–234.PubMedCrossRef 8. Chen HW, Chang YC, Lai YL, Chen YJ, Huang MJ, Leu YS, Fu YK, Wang LW, Hwang JJ: Change of plasma transforming growth factor-beta1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy. Jpn J Clin Oncol 2005, 35:427–432.PubMedCrossRef 9. Wei YS, Zhu YH, Du B, Yang ZH, Liang WB, Lv ML, Kuang XH, Tai SH, Zhao Y, Zhang L: Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 2007, 380:165–169.PubMedCrossRef 10. Wharton K, Derynck R: TGFbeta family signaling: novel insights in development and disease. Development 2009,

136:3691–3697.PubMedCrossRef 11. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.PubMedCrossRef 12. Kretschmer A, Moepert K, Dames S, Sternberger M, Kaufmann J, Klippel A: Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Oncogene 2003, 22:6748–6763.PubMedCrossRef Fludarabine order 13. Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O’Connor-McCourt MD, Siegel PM: Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 2009, 28:1005–1015.PubMedCrossRef 14. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, Shioda T, Roberts AB, Lechleider RJ: The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem 2000, 275:2115–2122.PubMedCrossRef 15. Massague J, Wotton D: Transcriptional control by the TGF-beta/Smad signaling system. Embo J 2000, 19:1745–1754.

Comments are closed.